FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
PCVX Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-452.63M
-296.79M
-170.6M
-121.39M
Net Income
-463.93M
-402.27M
-223.49M
-100.08M
Depreciation & Amortization
15.85M
10.17M
9.2M
3.46M
Deferred Income Taxes
0
0
0
0
Stock Based Compensation
84.82M
48.76M
23.65M
10.73M
Change in Working Capital
-54.9M
81.32M
12.74M
-37.01M
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
34.58M
11.22M
2.9M
-12.47M
Other Working Capital
-89.48M
70.09M
9.84M
-24.54M
Other Non-Cash Items
-34.47M
-34.77M
7.3M
1.5M
CF from Investing Activities
-2.01B
-773.31M
74.58M
-212.31M
Investments in Property, Plant & Equipment
-22.43M
-67.88M
-5.85M
-6.55M
Net Acquisitions
0
0
7k
26k
Investment Purchases
-3.09B
-1.33B
-102.75M
-336.34M
Sales/Maturities of Investments
1.2B
624.46M
183.17M
130.56M
Other Investing Activites
-96.73M
0
80.43k
-205.75k
CF from Financing Activities
2.45B
639.81M
861.55M
17.8M
Debt Repayment
0
0
0
0
Common Stock Issued
2.44B
636.04M
856.48M
13.9M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
12.85M
3.77M
5.07M
3.9M
Free Cash Flow
-475.05M
-364.67M
-176.44M
-127.95M
Operating Cash Flow
-452.63M
-296.79M
-170.6M
-121.39M
Capital Expenditures
-22.43M
-67.88M
-5.85M
-6.55M
Cash at Beginning of Period
398.55M
835.53M
69.86M
386.2M
Cash at End of Period
389.19M
398.55M
835.53M
69.86M
Net Change In Cash
-9.36M
-436.97M
765.67M
-316.34M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-924.39M
-522.13M
-298.64M
-198.56M
Net Income
-463.93M
-402.27M
-239.64M
-100.08M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-1.39B
-924.39M
-522.13M
-298.64M
Other Distributions
-463.93M
-402.27M
-223.49M
-100.08M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
270.15M
110.62M
31.65M
35.91M
Annual Depreciation
0
3.16M
9.2M
1.8M
Capital Expenditure
-22.43M
-67.88M
-5.85M
-6.55M
Net PPE
292.57M
175.34M
28.3M
40.67M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
